January 2022

Are We What We Eat? Impact of Diet on the Gut–Brain Axis in Parkinson’s Disease

Butyrate, Diet and Exercise, Gut Dysbiosis, Gut Microbiota, Gut Permeability / Leaky Gut, Gut-Brain axis, Parkinson's Disease, Pre-PD, Probiotics, Prebiotics and Symbiotics /

Parkinson’s disease is characterized by motor and non-motor symptoms, such as defects in the gut function, which may occur before the motor symptoms. To date, there are therapies that can improve these symptoms, but there is no cure to avoid the development or exacerbation of this disorder. Dysbiosis of gut microbiota could have a crucial […]

Are We What We Eat? Impact of Diet on the Gut–Brain Axis in Parkinson’s Disease Read More »

Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients

Butyrate, Gut Microbiota, Parkinson's Disease, Short Chain Fatty Acids /

Serum SCFAs are altered in PD patients, and the decrease of serum propionic acid level is correlated with motor symptoms, cognitive ability and non-depressed state. Thus, the gut microbial-derived SCFAs potentially affect Parkinson’s symptoms through the blood circulation. Propionic acid supplementation might ameliorate motor and non-motor symptoms of PD patients, although clinical trials are needed

Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients Read More »

Identification of an early-stage Parkinson’s disease neuromarker using event-related potentials, brain network analytics and machine-learning

Biomarkers, Parkinson's Disease, Pre-PD /

This pilot study found that BNA can identify patients with early PD using an advanced analysis of ERPs. These results need to be validated in a larger PD patient sample and assessed for people with premotor phase of PD. CLICK TO REVIEW

Identification of an early-stage Parkinson’s disease neuromarker using event-related potentials, brain network analytics and machine-learning Read More »

The second brain in Parkinson’s disease: fact or fantasy?

Fecal Transplants (FMT), Gut Microbiota, Probiotics, Prebiotics and Symbiotics /

We have briefly expressed three components that are significant in promoting the complex involvement of the gut within PD. Thorough research has looked into the physiology and symptoms of PD, with further exploration into the gut microbiota a crucial step in truly understanding the disease process. Adopting strategies to ensure stable, healthy microbial consumption along

The second brain in Parkinson’s disease: fact or fantasy? Read More »

Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Parkinson Disease Patients

Butyrate, Constipation, Gut Microbiota, Parkinson's Disease, Short Chain Fatty Acids /

Background and Objectives: Short-chain fatty acids (SCFAs) are gut microbial metabolitesthat promote the disease process in a rodent model of Parkinson’s disease (PD), but fecallevels of SCFAs in PD patients are reduced. Simultaneous assessments of fecal and plasmaSCFA levels, and their inter-relationships with the PD disease process are scarce. We aimedto compare fecal and plasma

Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Parkinson Disease Patients Read More »

Microbial pathogens induce neurodegeneration in Alzheimer’s disease mice: protection by microglial regulation

Enviromental, Parkinson's Disease, Root Canal, Viral / Bacterial Infections, Virus /

Exposure to systemic infections causes neurodegeneration in brain regions displaying amyloid pathology and high local microglia density. AD brains exhibit increased susceptibility to microbial PAMPs’ neurotoxicity, which accelerates neuronal death. Microglial modulation protects the brain from microbial TLR agonist PAMP-induced neurodegeneration. CLICK TO REVIEW

Microbial pathogens induce neurodegeneration in Alzheimer’s disease mice: protection by microglial regulation Read More »

A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders

Gut Dysbiosis, Gut Microbiota, Gut Permeability / Leaky Gut, Gut-Brain axis, Parkinson's Disease /

The human body is full of an extensive number of commensal microbes, consisting of bacteria, viruses, and fungi, collectively termed the human microbiome. The initial acquisition of microbiota occurs from both the external and maternal environments, and the vast majority of them colonize the gastrointestinal tract (GIT). These microbial communities play a central role in

A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders Read More »

Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson’s Disease

A-Synuclein, Dementia - Lewy Bodies, Parkinson's Disease /

Parkinson’s disease (PD) is the second most common neurodegenerative disorder and the fastest growing neurologic disease in the world, yet no disease-modifying therapy is available for this disabling condition. Multiple lines of evidence implicate the protein α-synuclein (α-Syn) in the pathogenesis of PD, and as such, there is intense interest in targeting α-Syn for potential disease modification. α-Syn

Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson’s Disease Read More »

Clinical and imaging evidence of brain-first and body-first Parkinson’s disease

A-Synuclein, Autonmic nervous system, Constipation, ENS, Gut Dysbiosis, iRBD, Non-Motor Symptoms, Orthostatic Hypotension, Parkinson's Disease, Pre-PD /

Braak’s hypothesis has been extremely influential over the last two decades. However, neuropathological and clinical evidence suggest that the model does not conform to all patients with Parkinson’s disease (PD). To resolve this controversy, a new model was recently proposed; in brain-first PD, the initial α-synuclein pathology arise inside the central nervous system, likely rostral to

Clinical and imaging evidence of brain-first and body-first Parkinson’s disease Read More »

A randomised, double-blind, placebo-controlled trial of Bifidobacterium bifidum CCFM16 for manipulation of gut microbiota and relief from chronic constipation

Butyrate, Constipation, Pre-PD, Short Chain Fatty Acids /

A variety of opinions exist on the potential of probiotics to provide relief from chronic constipation with much focus placed on their mechanism of action and causes of heterogeneity in the results of different studies. We aimed to determine the efficacy and safety of ingesting Bifidobacterium bifidum (B. bifidum) CCFM16 for 28 days to relieve

A randomised, double-blind, placebo-controlled trial of Bifidobacterium bifidum CCFM16 for manipulation of gut microbiota and relief from chronic constipation Read More »